This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Scio Diamond Demonstrates Its Commitment To Advancing Its Patented Technology In The Healthcare Industry

GREER, SC, Oct. 5, 2011 /PRNewswire/ - Scio Diamond Corporation (OTC:BB: SCIO) is pleased to announce its commitment to advancing its Patented Diamond Technology in the Healthcare Industry by shifting its Surgical Blade Project from R&D to now presenting its technology for future sales in medical devices.

With product in hand, Scio Diamond will now begin to explore, identify, and provide diamond products to potential customers who will customize the diamonds to meet the needs of their device products specifically for the medical industry.

Scio Diamond CEO, Joseph Lancia explains,  "We grow real diamonds in our labs with our patented technology, and as such, we have the ability to not only produce high grade gemstone products for the jewelry market, but also develop products to client specification for industries such as the medical industry."

According to our research, diamond is the only substance known that can maintain a cold-contact surface while effectively transmitting laser energy.  The density of its molecular structure permits it to sharpen to an astonishingly fine edge of 25 Nanometer.  The diamond blade, which is forty times (40x) sharper than a traditional steel scalpel and durable enough to last up to 200 full surgical procedures, offers surgeons the ability to operate cost-effectively with great precision and improved surgical outcomes.    Clinical studies have shown that when the Diamond Laser Surgical System is used, surgery time is significantly reduced and wounds heal faster and with less exuberance and discomfort due to reduced swelling and bruising.  The Scio Diamond Blade product, which will be ready for market will initially benefit Aesthetic and Reconstructive Surgery, Dermatology, ENT (Ear, Nose and Throat), Neurosurgery, Pediatric Surgery, and Orthopedic Surgery.

The company will initially target approximately 33,000 office-based surgery practices in the US that perform cosmetic surgery as well as expand to other emerging markets worldwide.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs